Navigation Links
Favrille to Present at BIOCOM Investor Conference, Acumen BioFin Rodman & Renshaw Healthcare Conference and CIBC World Markets Healthcare Conference
Date:10/26/2007

Live Webcasts from San Diego on November 2nd and New York on November 5th

SAN DIEGO, Oct. 26 /PRNewswire-FirstCall/ -- Favrille, Inc. (Nasdaq: FVRL), a biopharmaceutical company developing patient-specific, active immunotherapies for the treatment of cancer, today announced that the Company will present at three upcoming investor conferences:

(Logo: http://www.newscom.com/cgi-bin/prnh/20031013/LAM095LOGO)

-- Richard Ghalie, M.D., Chief Medical Officer, will present at the BIOCOM

Investor Conference at 11:00 a.m. Pacific time on Friday, November 2,

2007, from the San Diego Marriott Del Mar;

-- John P. Longenecker, Ph.D., President and Chief Executive Officer, will

present at the Acumen BioFin Rodman & Renshaw Healthcare Conference at

10:35 a.m. Eastern time on Monday, November 5, 2007, from the New York

Palace Hotel; and

-- Dr. Longenecker will also present at the CIBC World Markets Healthcare

Conference at 1:20 p.m. Eastern time on Monday, November 5, 2007, from

the Waldorf-Astoria in New York.

Live webcasts of all three presentations can be accessed at http://www.favrille.com. Replays will be available approximately one hour after each presentation and archived for one month.

About Favrille, Inc.

Favrille, Inc. is a biopharmaceutical company focused on the development and commercialization of targeted immunotherapies for the treatment of cancer and other diseases of the immune system. The Company's lead product candidate, FavId, is based upon unique genetic information extracted from a patient's tumor. FavId is currently under investigation in a pivotal Phase 3 clinical trial for patients with follicular B-cell NHL and Phase 2 clinical trials in other B-cell NHL indications. The Company is developing additional applications based on its immunotherapy expertise and proprietary cost-effective manufacturing technology, including a second product candidate, FAV-201, for the treatment of cutaneous T-cell lymphoma.


'/>"/>
SOURCE Favrille, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies
2. Wisconsin firms to present at Cleantech venture capital event
3. New Sonic Foundry search engine finds words, phrases in video presentations
4. Lone Wisconsin firm to present at InvestMidwest
5. Sonic Foundry creates search engine for 7,000 expert video presentations
6. InvestMidWest calls for business presentations
7. Wicab to present BrainPort at Boston conference
8. Three more Wisconsin firms to present at venture forum
9. Six Wisconsin firms to present at BIO Mid-America VentureForum
10. New Health and Human Services representative for Midwest
11. Top 20 big pharmas represent majority of world pharma market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2017)... , ... February 21, 2017 , ... ... cell therapy manufacturing facility at its headquarters laboratory in Poway, California. Based ... the experience of both in-house personnel and consultants, VetStem constructed and validated a ...
(Date:2/21/2017)... and VANCOUVER, British Columbia , ... OGXI ) today announced that apatorsen results from two randomized ... of Clinical Oncology (ASCO) 2017 Genitourinary Cancers Symposium, held February ... . Clinical data from trials in bladder and prostate ... administered in combination with standard-of-care treatments. ...
(Date:2/21/2017)... 2017   Logicalis Healthcare Solutions , the healthcare-focused ... managed services provider ( www.us.logicalis.com ), today announced a ... The new service will help hospital CIOs make the ... physicians, nurses and other clinicians immediate access to a ... will allow hospital IT staff to focus on broader ...
(Date:2/21/2017)... SAN FRANCISCO , Feb. 21, 2017   ... growing genetic information companies, today announced that members of ... and Company 37th Annual Health Care Conference on Monday, ... 1:00 p.m. Pacific in Boston, Massachusetts ... the presentation may be accessed by visiting the investors ...
Breaking Biology Technology:
(Date:2/21/2017)... 2017 Der weltweite Biobanking-Sektor wird ... einem Gespräch mit mehr als 50 Vertretern aus verschiedenen Branchen ... gilt, um diese Prognose zu realisieren. ... Zu den ... finanziellen Mittel für die Biobank, die Implementierung Zeit sparender ...
(Date:2/13/2017)... Former 9/11 Commission border counsel and Special ... Kephart of Identity Strategy Partners, LLP, today releases ... "Executive Order: Protecting the Nation From Foreign Terrorist Entry ... "As President Trump,s ,Travel Ban, Executive Order gains more ... the travel ban, it is important that our national ...
(Date:2/8/2017)... 7, 2017  Aware, Inc. (NASDAQ: AWRE ), ... financial results for its quarter and year ended December 31, ... 2016 was $3.9 million compared to $6.9 million in the ... of 2016 was $0.6 million compared to $2.6 million in ... quarter of 2016 was $0.5 million, or $0.02 per diluted ...
Breaking Biology News(10 mins):